Chimerix to Participate in Maxim Group Panel Discussion

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that Josh Allen, Ph.D., its Chief Technology Officer of Imipridones, will participate in a panel discussion titled “Exploring New Targets for Pediatric Brain Cancer.” This event is hosted by Maxim Group and is scheduled for May 19, 2022, at 9:00 a.m. ET. An audio webcast of the event will be accessible on Chimerix's Investor Relations website for approximately 90 days. Chimerix is dedicated to developing medicines that enhance and prolong patients' lives. Notably, the FDA approved its drug TEMBEXA for smallpox treatment in June 2021.

DURHAM, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Josh Allen, Ph.D., Chief Technology Officer of Imipridones, will participate in a panel discussion hosted by Maxim Group. The event, “Exploring New Targets for Pediatric Brain Cancer,” will take place on Thursday, May 19, 2022 at 9:00 a.m. ET.

An audio webcast of the event will be available on the Investor Relations section of Chimerix's website at https://ir.chimerix.com/, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACTS:

Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When is the Chimerix panel discussion on pediatric brain cancer?

The panel discussion will take place on May 19, 2022, at 9:00 a.m. ET.

Who will represent Chimerix at the Maxim Group event?

Josh Allen, Ph.D., the Chief Technology Officer of Imipridones at Chimerix, will represent the company.

Where can I listen to the Chimerix panel discussion?

The audio webcast will be available on the Investor Relations section of Chimerix's website.

What is the mission of Chimerix?

Chimerix aims to develop medicines that significantly improve and extend the lives of patients with deadly diseases.

What drug did Chimerix receive FDA approval for?

Chimerix received FDA approval for TEMBEXA, which is used for the treatment of smallpox.